Kim is collaborating with Kansas State University's Kyeong-Ok Chang, a virologist in the diagnostic medicine and pathobiology department, and with Duy Hua and William Groutas, who are medicinal chemists at Kansas State University and Wichita State University, respectively.
"We designed a series of inhibitors for 3C-like protease, and identified a couple of promising compounds through various steps involving exploring the relationship between a compound structure and its biological activity," Kim said. "Some of the work has been supported by another grant from the Winn Feline Foundation. The compounds effective against FIP virus are currently under investigation for pharmacokinetic properties in cats in collaboration with Dr. Niels C. Pedersen at the University of California, Davis. This will give us valuable information that will guide our further efforts in moving forward with development of a safe and efficacious antiviral drug for FIP."
Kim continues to probe the possibility of developing antiviral compounds that are active against both FIPV and vs-FCV. The drug discovery and development process is very long and expensive, and can be fraught with difficulties.
"More and more focus has been placed on the development of broad-spectrum antiviral drugs that work against multiple viruses," Kim said. "That is the reason we also generated a series of compounds with broad activity against FIP and vs-FCV based on the structural and functional similarities of the proteases of these viruses. For the next three years, supported by the Morris Animal Foundation grant, we will characterize those compounds for drug-like properties and also identify additional backup compounds. In addition to protease inhibitors, we identified a cellular enzyme that is important in both FIPV and FCV. The grant also will support our research
|Contact: Yunjeong Kim|
Kansas State University